Using oral absorbents and probiotics to slow down chronic kidney disease progression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of an oral uremic toxin absorbent, specifically activated bamboo charcoal, alongside probiotics to reduce the levels of harmful uremic toxins in patients with chronic kidney disease (CKD). The approach aims to prevent the absorption of these toxins, which are linked to kidney function decline and cardiovascular risks. By targeting protein-bound uremic toxins like indoxyl sulfate and p-cresol, the study seeks to improve kidney function and overall health outcomes for CKD patients. Participants will be monitored for changes in kidney function and toxin levels throughout the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 20 years old on the day of screening.
2. CKD patients with eGFR 15 \< eGFR \<45 ml/min/1.73m2 and UACR \> 100 mg/g in a stable status, creatinine elevated less than 0.3 mg/dL in at least 30 days before enrollment.

Exclusion Criteria:

1. Baseline estimated glomerular filtration rates (eGFR) \< 15 ml/min/1.73m2 according to MDRD equation.
2. Patients in severe malnutrition status, albumin less than 2.0 g/dL
3. Patients in severe anemia or active gastrointestinal bleeding with hemoglobulin \< 8 g/dL.
4. Peptic ulcer, esophageal varices, ileus or under fasting status
5. Previous gastrointestinal operation.
6. Chronic constipation, as defined with less than 3 bowel movements per week, straining, hard stools, incomplete evacuation and inability to pass stool. If usage of oral laxatives can achieve bowel movement, this patient will not be excluded.
7. Patients with major hemorrhage, as defined with acute hemorrhage and requirement of blood transfusion during index admission.
8. Patients with a biopsy proved or clinically diagnosed advanced liver cirrhosis, Child classification B or C.
9. Solid organ or hematological transplantation recipients.
10. Patients with oliguric kidney injury, as defined with less than 500 cc/day.
11. Evidence of obstructive kidney injury or polycystic kidney disease.
12. Antibiotics or probiotics treatment within the last 2 weeks before enrollment and during follow-up period.
13. Presence or history of malignant neoplasms within the past 5 years prior to the day of screening.

Where it's running

• Ntuh
  Taipei, Taiwan Recruiting

Study contacts

• Principal investigator: Chau chung Wu, Ph.D. — National Taiwan University Hospital
• Study coordinator: Chau chung Wu, Ph.D.
• Email: Chauchungwu@ntu.edu.tw
• Phone: 02-23123456

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fostering Self-Empowerment in CKD Patients Through Food Choice Mapping

  This project tests a Renal dining map app to help CKD patients in Singapore choose foods when dining out and see if it improves empowerment and well‑being.

  Recruiting Singapore Institute of Technology · Singapore · NCT07804316

• Self-Management Data and Disease Progression in CKD

  This study tests whether patient-recorded self-management data collected via a mobile app can be linked to CKD progression in adults seen at a university hospital.

  Recruiting Chungnam National University Hospital · Daejeon, DJ · NCT07754097

• Enarodustat for Anemia in Non-Dialysis CKD Patients

  This study tests whether enarodustat can help increase hemoglobin safely in adults with CKD who aren’t on dialysis, grouping participants by inflammation level.

  Recruiting Huashan Hospital · Shanghai, Shanghai Municipality · NCT07741279

• Periodontal Health in Rare Kidney Conditions and Controls

  This study tests how common periodontitis is in people with rare kidney disorders and compares it to CKD patients and people without kidney disease.

  Recruiting Institutul Clinic Fundeni · Bucharest · NCT07575347

• AdiaVita regenerative therapy for chronic kidney disease

  This trial tests whether AdiaVita (umbilical cord blood stem cells and exosomes plus glutathione) can improve kidney function in adults with stage 2–4 chronic kidney disease.

  Recruiting Phase 1 Adia Med of Winter Park LLC · Winter Park, Florida · NCT07572890

• HTD1801 vs placebo for kidney protection in type 2 diabetes and CKD

  This trial tests whether HTD1801 can slow kidney decline in adults with type 2 diabetes and chronic kidney disease.

  Recruiting Phase 2 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences · Weifang, Shandong · NCT07496177

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.